These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 10227702)

  • 1. Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides.
    Juliano RL; Alahari S; Yoo H; Kole R; Cho M
    Pharm Res; 1999 Apr; 16(4):494-502. PubMed ID: 10227702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progress in the delivery of therapeutic oligonucleotides: organ/cellular distribution and targeted delivery of oligonucleotides in vivo.
    Wang L; Prakash RK; Stein CA; Koehn RK; Ruffner DE
    Antisense Nucleic Acid Drug Dev; 2003; 13(3):169-89. PubMed ID: 12954117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspects of the transport and delivery of antisense oligonucleotides.
    Juliano RL; Yoo H
    Curr Opin Mol Ther; 2000 Jun; 2(3):297-303. PubMed ID: 11249624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological barriers to therapy with antisense and siRNA oligonucleotides.
    Juliano R; Bauman J; Kang H; Ming X
    Mol Pharm; 2009; 6(3):686-95. PubMed ID: 19397332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides.
    White PJ; Anastasopoulos F; Pouton CW; Boyd BJ
    Expert Rev Mol Med; 2009 Mar; 11():e10. PubMed ID: 19302730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell membranes as barriers for the use of antisense therapeutic agents.
    Jääskeläinen I; Urtti A
    Mini Rev Med Chem; 2002 Aug; 2(4):307-18. PubMed ID: 12370052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the lung using siRNA and antisense based oligonucleotides.
    Moschos SA; Spinks K; Williams AE; Lindsay MA
    Curr Pharm Des; 2008; 14(34):3620-7. PubMed ID: 19075738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligonucleotide conjugates as potential antisense drugs with improved uptake, biodistribution, targeted delivery, and mechanism of action.
    Manoharan M
    Antisense Nucleic Acid Drug Dev; 2002 Apr; 12(2):103-28. PubMed ID: 12074364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microinjection of antisense oligonucleotides to assess G-protein subunit function.
    Kleuss C; Schultz G; Wittig B
    Methods Enzymol; 1994; 237():345-55. PubMed ID: 7935009
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides.
    Geary RS; Norris D; Yu R; Bennett CF
    Adv Drug Deliv Rev; 2015 Jun; 87():46-51. PubMed ID: 25666165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and biodistribution of phosphorodiamidate morpholino antisense oligomers.
    Amantana A; Iversen PL
    Curr Opin Pharmacol; 2005 Oct; 5(5):550-5. PubMed ID: 16087398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced delivery of antisense oligonucleotides with fluorophore-conjugated PAMAM dendrimers.
    Yoo H; Juliano RL
    Nucleic Acids Res; 2000 Nov; 28(21):4225-31. PubMed ID: 11058121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide-mediated cellular delivery of antisense oligonucleotides and their analogues.
    Gait MJ
    Cell Mol Life Sci; 2003 May; 60(5):844-53. PubMed ID: 12827274
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides.
    Levin AA
    Biochim Biophys Acta; 1999 Dec; 1489(1):69-84. PubMed ID: 10806998
    [No Abstract]   [Full Text] [Related]  

  • 15. Albumin-protamine-oligonucleotide-nanoparticles as a new antisense delivery system. Part 2: cellular uptake and effect.
    Weyermann J; Lochmann D; Georgens C; Zimmer A
    Eur J Pharm Biopharm; 2005 Apr; 59(3):431-8. PubMed ID: 15760723
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The disposition (ADME) of antisense oligonucleotides.
    Dvorchik BH
    Curr Opin Mol Ther; 2000 Jun; 2(3):253-7. PubMed ID: 11249618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of carrier size in the pharmacodynamics of antisense and siRNA oligonucleotides.
    Huang L; Sullenger B; Juliano R
    J Drug Target; 2010 Sep; 18(8):567-74. PubMed ID: 20367081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The delivery of antisense therapeutics.
    Akhtar S; Hughes MD; Khan A; Bibby M; Hussain M; Nawaz Q; Double J; Sayyed P
    Adv Drug Deliv Rev; 2000 Oct; 44(1):3-21. PubMed ID: 11035194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense oligonucleotides for target validation in the CNS.
    Ho SP; Hartig PR
    Curr Opin Mol Ther; 1999 Jun; 1(3):336-43. PubMed ID: 11713799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Smart" delivery of antisense oligonucleotides by anionic pH-sensitive liposomes.
    Fattal E; Couvreur P; Dubernet C
    Adv Drug Deliv Rev; 2004 Apr; 56(7):931-46. PubMed ID: 15066753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.